Hidden or misreported trial results cause widespread patient harm

BMJ (Online)

Volumn 347, Issue 7916, 2013, Pages

  Light, Donald W ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

DRUG INDUSTRY; DRUG INFORMATION; DRUG RECALL; DRUG RESEARCH; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HARM REDUCTION; HEALTH CARE SYSTEM; HUMAN; INFORMATION DISSEMINATION; INFORMATION PROCESSING; LETTER; METHODOLOGY; PATENT; PATIENT SAFETY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 84880094680     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4393     Document Type: Letter

References (5)

1. Loder E, Godlee F, Barbour V, Winkler M. Restoring the integrity of the clinical trial evidence base. BMJ 2013;346:f3601. (13 June.)
2. Light D, Lexchin J. Pharmaceutical R&D - what do we get for all that money? BMJ 2012;344:e4348.
3. Light DW, Lexchin J, Darrow J. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics 2013 [forthcoming].
4. Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med 2012;172:1680-1.
5. Morgan SG, Bassett KL, Wright JM, Evans RG, Barer ML, Caetano PA, et al. "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. BMJ 2005;331:815-6. (Pubitemid 41442361)